Series A - Purespring Therapeutics - 2020-11-19 - Crunchbase

Purespring Therapeutics raised $59613150 on 2020-11-19 in Series A. Syncona Partners LLP Syncona Partners LLP is a healthcare company focused on investing in and building global …

CouponFollow Extension

$59613150
OFF

Series A - Purespring Therapeutics - 2020-11-19 - Crunchbase

6 days from now

Purespring Therapeutics raised $59613150 on 2020-11-19 in Series A. Syncona Partners LLP Syncona Partners LLP is a healthcare company focused on investing in and building global …

crunchbase.com

$59.68
OFF

Purespring Therapeutics Stock Price, Funding, Valuation, Revenue ...

6 days from now

Oct 9, 2024 · Purespring Therapeutics's latest funding round was a Series A for $59.68M on November 19, 2020. Date. Round. Amount. ... provided by VentureSource, or based on a …

cbinsights.com

£45
OFF

Syncona Founds Purespring With A £45m Series A Financing

6 days from now

Jul 30, 2021 · Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, announces the foundation of a new …

purespringtx.com

£45
OFF

Syncona Founds Purespring With A £45m Series A Financing

6 days from now

19.11.20. Share this page. Further reading. Financial; ... Purespring Therapeutics (Purespring), with a £45.0 million Series A financing. Syncona’s holding value in Purespring is £3.9 million …

synconaltd.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

globenewswire.com

£19
OFF

Syncona Commits Another £19.9m To Purespring Therapeutics

6 days from now

Oct 9, 2024 · Syncona has invested a further £19.9m in Purespring Therapeutics as part of an £80m oversubscribed Series B financing for that company. Syncona formed part of a leading …

quoteddata.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

businessinsider.com

$104711631
OFF

Series B - Purespring Therapeutics - 2024-10-09 - Crunchbase

6 days from now

Oct 9, 2024 · Purespring Therapeutics raised $104711631 on 2024-10-09 in Series B. Sofinnova Partners Sofinnova Partners is a venture capital firm that invests in the life sciences sector, …

crunchbase.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 – Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

purespringtx.com

$105
OFF

Purespring Therapeutics Raised A $105M Series B Earlier This Month …

6 days from now

Oct 24, 2024 · CEO Julian Hanak describes how Purespring focuses on targeting podocytes, a cell type that plays a role in various kidney diseases. Key preclinical data for the lead IgA …

biotechtv.com

$57059894
OFF

Series A - ATB Therapeutics - 2024-11-18 - Crunchbase

6 days from now

5 days ago · ATB Therapeutics raised $57059894 on 2024-11-18 in Series A. EQT Life Sciences EQT Life Science develops novel medications, devices, and tools to address people's health …

crunchbase.com

$19803671
OFF

Series A - Glyscend Therapeutics - 2020-06-11 - Crunchbase

6 days from now

Jun 11, 2020 · Glyscend Therapeutics raised $19803671 on 2020-06-11 in Series A. Search Crunchbase. Start Free Trial . Chrome Extension. ... Announced Date Jun 11, 2020; Closed …

crunchbase.com

$26000000
OFF

Series A - Structure Therapeutics - 2020-03-11 - Crunchbase

6 days from now

Mar 11, 2020 · Structure Therapeutics raised $26000000 on 2020-03-11 in Series A. Qiming Venture Partners Qiming Venture Partners is a venture capital firm investing in …

crunchbase.com

FAQs about Series A - Purespring Therapeutics - 2020-11-19 - Crunchbase Coupon?

Does purespring therapeutics have a series B financing?

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona ...

Who is purespring Therapeutics?

Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally. ...

What is purespring?

Purespring seeks to advance gene therapies for the treatment of chronic renal diseases that are currently poorly addressed with existing treatments. ...

What is purespring AV gene therapy?

Purespring is one of the first AAV gene therapy companies focused on the kidney globally and will seek to treat a number of debilitating chronic diseases that are currently poorly addressed with existing therapies. ...

Where can I find more information about purespring TX?

For more information please visit: purespringtx.com and follow us on LinkedIn. About Syncona Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need. ...

How does purespring treat kidney disease?

Purespring is the first company to successfully treat kidney disease models by directly targeting the podocyte, a specialised cell implicated in approximately 60% of renal diseases, through its proprietary adeno-associated viral (AAV) gene therapy platform. The Company currently has a pipeline of programmes in development. ...